Skip to main
DNTH
DNTH logo

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc. has demonstrated a positive financial outlook driven by an increase in its target price to $44, reflecting growing confidence in the company's innovative pipeline of monoclonal antibodies. The firm's dedicated approach to developing next-generation complement therapeutics positions it favorably in the clinical-stage biotechnology landscape, particularly in addressing severe autoimmune and inflammatory diseases. With a seasoned team of biotech and pharmaceutical executives, Dianthus is well-equipped to advance its lead candidate, DNTH103, which could significantly enhance treatment options for patients.

Bears say

Dianthus Therapeutics Inc. faces a significant financial constraint due to its reliance on external funding to advance its clinical pipeline, which includes the development of DNTH103. The company has emphasized that an inability to secure adequate funds could severely hinder their operational progress and limit the advancement of their therapeutic candidates. This funding dependency raises concerns about the sustainability of its research and development efforts in a competitive biotech landscape.

DNTH has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Buy based on their latest research and market trends.

According to 8 analysts, DNTH has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $66.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $66.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.